Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1a antibody, in a phase III randomized study of advanced colorectal cancer.
Kurzrock R, Hickish T, Wyrwicz L, Saunders M, Wu Q, Stecher M, Mohanty P, Dinarello CA, Simard J. Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1a antibody, in a phase III randomized study of advanced colorectal cancer. Oncoimmunology. 2019; 8(3):1551651.